Ichor Holdings Ltd. (Nasdaq: ICHR) Posts Results – Shares drop

Ichor Holdings, Ltd. – Nasdaq: ICHR

Shares of Ichor Holdings, Ltd. dropped after the firm released financial results for the 4th quarter and gave guidance for 2017. Ichor Holdings, Ltd. trades on the Nasdaq under ticker symbol ICHR.

Fremont, CA-based Ichor Holdings, Ltd. engages in the design, engineering, and manufacture of fluid delivery subsystems for semiconductor capital equipment in the United States, the United Kingdom, Singapore, and Malaysia. It primarily offers gas and chemical delivery subsystems that are used in the manufacturing of semiconductor devices. Ichor Holdings employees are strategically located to provide their customers with the highest level of customer service and support from their program management, sales, engineering, and executive management teams.

Ichor expects sales of approximately $131 million for the fourth quarter, and approximately $405 million for the 2016 fiscal year. Additionally, Ichor expects sales for the first quarter of the 2017 fiscal year to be higher than for the fourth quarter of the 2016 fiscal year.

Ichor Holdings has posted negative EPS in 2014 and 2015: -$0.02 and -$0.40 respectively. However sales increased from $249 million in 2014 to $290.6 million in 2015. Five firms follow Ichor Holdings with three rating ICHR a “Strong Buy” and two rating ICHR a “Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/10/2017
Ticker Symbol ICHR
Last Price a/o 4:00 PM EST  $                    13.40
Average Volume 162,000
Market Cap $320.5 million
Sales $338.8 million
Shares Outstanding 23.92 million
Share Float 20.83 million
Shortable Yes
Optionable No
Inside Ownership 12.20%
Short Float 0.87%
Short Interest Ratio 1.12
Quarterly Return
YTD Return 23.84%
Year Return

Signal Genetics Inc. (Nasdaq: SGNL) Rockets 240%+ Amid Very Heavy Volume

Signal Genetics, Inc. – Nasdaq: SGNL

Shares of Carlsbad, CA-based Signal Genetics skyrocketed over 240% today. The thinly traded shares are traded on the Nasdaq under the ticker symbol SGNL. On Tuesday SGNL closed at $4.79 and today the high has been $17.49 on unusually heavy volume.

Investors seem to be snapping up shares on the back of news that Signal Genetics Inc. has agreed to a merger with Miragen Therapeutics Inc. Also, included in the merger will be the sale of Signal’s MyPRS intellectual property assets.

Signal Genetics, Inc. is a molecular genetic diagnostic company. Signal provides diagnostic services that assist physicians in decision making for the care of cancer patients. The company primarily offers Myeloma Prognostic Risk Signature test – a test for the presence of specific groups of genes that could predict low or high level risk of early relapse in patients suffering from multiple myeloma.

The nano-cap biotech company has posted negative EPS since 2011 with a loss of $21.00 reported for 2015. Sales have been more optimistic with Signal reporting $2.5 million in 2015. Two firms cover Signal Genetics and each rate SGNL shares as a “Strong Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/10/2017
Ticker Symbol SGNL
Last Price a/o 3:58 PM EST  $                    16.75
Average Volume 96,000
Market Cap $3.69 million
Sales 3.2 million
Shares Outstanding 0.77 million
Share Float 0.47 million
Shortable Yes
Optionable No
Inside Ownership 5.30%
Short Float 1.31%
Short Interest Ratio 0.06
Quarterly Return -34.83%
YTD Return -4.39%
Year Return -54.45%

Allscripts Healthcare Solutions Inc. (Nasdaq: MDRX) Posts Financial Results – Shares Rise

Allscripts Healthcare Solutions, Inc. – Nasdaq: MDRX

Allscripts Healthcare Solutions, Inc., traded on the Nasdaq under ticker symbol MDRX, announced preliminary financial results for the fourth quarter ended Dec. 31, 2016. The company anticipates consolidated bookings for the 4th quarter of 2016 to exceed $400 million, a fourth-quarter record. This result implies annual bookings growth of over 17 percent. Shares of MDRX hav responded by increasing almost 10% in early trading.

Paul M. Black, Allscripts’ Chief Executive Officer stated in a press release “Our investments in our solutions continue to increase our competitiveness, reflected in signed agreements which added the largest number of new Sunrise facilities in our history. Our initial outlook for 2017 illustrates confidence this growth momentum will continue this year across Allscripts comprehensive offerings to payers and providers globally.”

Chicago, IL-based Allscripts Healthcare Solutions Inc. is a leader in healthcare information technology solutions that advance clinical, financial, and operational results. Twenty-one firms follow Allscripts Healthcare and twelve rate MDRX as a “Hold”, one rates it as a “Buy” and eight rate MDRX as a “Strong Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

Asure Software, Inc. (Nasdaq: ASUR) Closes Three Deals – Shares Rise

Asure Software, Inc. – Nasdaq: ASUR

Asure Software, Inc., based in Austin, TX, closed three strategic acquisitions and provided financial guidance for fiscal 2017. Its shares, traded on the Nasdaq under ticker ASUR, have risen almost 30% in response.

Asure Software, Inc. provides cloud-based software-as-a-service (SaaS) time and labor management, and workspace management solutions worldwide. On January 1, 2017, Asure Software closed three strategic acquisitions: Personnel Management Systems, Inc. (PMSI), a provider of outsourced HR solutions, Corporate Payroll, Inc. (Payroll Division) (CPI), a provider of payroll services in Ohio, and Payroll Specialties NW, Inc. (PSNW), a provider of payroll services in Oregon.

CEO Goepel stated: “These acquisitions allow us to grow and make strategic decisions about our growth. Since joining as CEO in 2009, Asure had a $6 million market cap and was in a turnaround situation. Now that the transition is complete, we have evolved into a growth company, with a world-class customer base, industry-leading solutions, and a strong financial profile and outlook. With the completion of the recent capital raise, in which insiders participated for greater than 10%, and now the closing of these acquisitions, we are in a position to make strategic decisions to fund for accelerated growth, while continuing to drive strong EBITDA and cash flow.”

Goepel also gave guidance for 2017 “For the full year of 2017, we expect revenue to range between $45 million and $47 million, and EBITDA (excluding one-time expenses) to be between $9 million and $9.5 million.”

Five firms follow Asure Software, Inc. and all five rate ASUR as a “Strong Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/10/2017
Ticker Symbol CUDA
Last Price a/o 3:59 AM EST  $                    10.93
Average Volume 92,800
Market Cap $90.6 million
Sales $32.6 million
Shares Outstanding 8.29 million
Share Float 7.34 million
Shortable Yes
Optionable No
Inside Ownership 10.40%
Short Float 3.78%
Short Interest Ratio 2.99
Quarterly Return 58.41%
YTD Return 28.44%
Year Return 145.62%

Exelixis Inc. (Nasdaq: EXEL) Shares Higher on Resolution of Dispute with Genentech

Exelixis, Inc. – Nasdaq: EXEL

Genentech’s announcement to stop charging Exelixis, Inc. some expenses under their collaboration agreement sent EXEL shares almost 15% higher today. Exelixis Inc. is a San Fransico, CA-based biopharmaceutical company that develops molecular therapies with the potential to improve the treatment of cancer.

Exelixis and Genentech have shared promotional costs since commercial activities were initiated in early 2013. As detailed in previous regulatory filings, Exelixis charged its Profit and Loss Statement approximately $38 million for promotional costs through the third quarter of 2016. With the new approach that Genentech has adopted unilaterally, Exelixis’ liability for promotional costs will be reduced to approximately $15 million for the same period. Exelixis Inc. will not have to pay$18.7 million in disputed costs, and Exelixis will receive $7.1 million for expenses they had already paid – plus interest.

Six firms follow Exwlixis, INC. All six rate shares of EXEL as a “String Buy” The consensus price target is $21.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/9/2017
Ticker Symbol EXEL
Last Price a/o 4:00 PM EST  $                    17.58
Average Volume 5.98 million
Market Cap $4.93 Billion
Sales $123.8 million
Shares Outstanding 280.3 million
Share Float 260.59 million
Shortable Yes
Optionable Yes
Inside Ownership 0.80%
Short Float 6.52%
Short Interest Ratio 2.84
Quarterly Return 35.75%
YTD Return 17.91%
Year Return 259.51%

 

Merrimack Pharmaceuticals Inc. (Nasdaq: MACK) Gaps up – Comes Down

Merrimack Pharmaceuticals, Inc. – Nasdaq: MACK

Heavy social media chatter focused on Merrimack Pharmaceuticals this morning. Mack, traded on the Nasdaq, shares were sent higher ($5.61) before settling back into the high range of the $3 handle. MACK closed Friday at $3.60.

The Cambridge, MA-based biotechnology firm had announced agreement to sell its Onivide and generic version of Doxil to Ipsen for a reported $1.025 Billion. $200 million of the proceeds would be used as a special cash dividend to shareholders of MACK.

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error.

Three firms follow Merrimack Pharmaceuticals. All three give MACK a “Hold” rating. Their consensus price target is $7.00. Reported EPS for MACK has never been positive and last year was the largest EPS loss for Merrimack at -$1.33. Sales have fared better with Merrimack reporting a high-water marke last year of $102 million but only $89.3 million in 2015.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/9/2017
Ticker Symbol MACK
Last Price a/o 10:00 AM EST  $                      4.07
Average Volume 3.2 million
Market Cap $492 million
Sales $104.5 million
Shares Outstanding 136.8 million
Share Float 122.4 million
Shortable Yes
Optionable Yes
Inside Ownership 0.10%
Short Float 30.74%
Short Interest Ratio 11.73
Quarterly Return -39.80%
YTD Return -11.76%
Year Return -45.78%

Live Ventures (Nasdaq: LIVE) Faces Accusations of Manipulation

Live Ventures Incorporated – Nasdaq: LIVE

Live Ventures Incorporated Inc. is facing accusations that it manipulated material financial information to boost the price of its stock. Traded on the Nasdaq, LIVE shares traded near $30 after an earnings report that exceeded analyst expectations. On Friday, shares of LIVE closed just over $18 on very heavy volume.

On Friday published reports accused Live Ventures of paying $2 million to aggressively hype its shares. Unconfirmed reports suggest that recipient of the payment was a firm that had previously hyped shares of ForceField Energy – a stock that was delisted and went to $0. Reports further allege that Live Ventures created one-time gains in earnings through various discretionary, questionable accounting methods. The report further allegedly suggests that the reported GAAP earnings for the last quarter are suspicious and that the true earnings figure should have represented a loss and not a profit. Reports claim that the cash-on-hand valuation of LIVE stock is $0.28.

In response, Live Ventures issued a press release claiming that CEO John Isaac had purchased $250,000 worth of LIVE on the open market. “The purchase of this stock is representative of my confidence in the potential of Live Ventures stock, as well as the continued execution of its business plan,” Isaac says in a statement.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) Announces Merger – Shares Higher

OncoGenex Pharmaceuticals, Inc. – Nasdaq: OGXI

OncoGenex Pharmaceuticals, Inc. shares, traded on the Nasdaq under ticker OGXI, are up over 50% on heavy volumes. OncoGenex develops novel therapeutics that target important mechanisms of treatment resistance in cancer with the potential to redefine treatment outcomes for patients with a variety of cancers.

Price action is likely due to the announcement that OncoGenex Pharmaceuticals, Inc. will be merging with privately-held Achieve Life Science Inc. The proposed merger will create a clinical-stage company focused on clinical and commercial development of cytisine, a selective nicotine receptor partial agonist currently in late-stage development for smoking cessation.  Two recent Phase 3 trials in over 2,000 patients using cytisine as a smoking cessation aid have been completed, with positive results published in the New England Journal of Medicine. In addition to cytisine, the combined company’s pipeline will also include apatorsen, a once-weekly intravenous drug designed to inhibit production of heat shock protein 27 to disable cancer cells’ defenses and overcome treatment resistance.

Several firms have assigned a rating of “Buy” to OGXI. OncoGenex Pharmaceuticals, Inc. reported a EPS loss of $0.64 but that has steadily improved since 2013 when it delclared an EPS loss of $2.17. Sales have not fared as well. OncoGenex Pharmaceuticals, Inc. reported 2013 sales of $29.9 million and $18.2 million in 2015. Shares outstanding of OGXI have increased from 14.68 million in 2013 to 26.15 million in 2015.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

EnteroMedics Inc. (Nasdaq: ETRM) Makes Larges Gains in Pre-Market

EnteroMedics Inc.– Nasdaq: ETRM

Shares of MN-based EnteroMedics Inc. are up over 80% in pre-market trading on heavy volume. Shares are traded on the Nasdaq under the ticker symbol ETRM. ETRM closed at $2.09 on Wednesday, $3.97 on Thursday, and have traded as high as $7.62.

EnteroMedics® Inc. develops therapies for obesity. It has developed vBloc® vagal blocking therapy, a patented therapeutic approach to treat a range of gastrointestinal and metabolic diseases. vBloc® is a weight loss treatment that addresses the growing global health crises associated with obesity and its co-morbidities, such as diabetes and hypertension.

vBloc® Therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, controls both hunger and fullness by blocking the primary nerve which regulates the digestive system. The Maestro Rechargeable System has received Food and Drug Administration (FDA) approval as well as CE Mark in Europe, and has been listed on the Australian Register of Therapeutic Goods (ARTG) by the Therapeutic Goods Administration (TGA) for supply in Australia.

Price action seems to be motivated by news that MedStar Health in Maryland and Roper St. Francis in South Carolina, both vBloc institutes, have implanted vBloc Neurometabolic therapies.

EnteroMedics Inc. has no reported sales. Only one firm follows ETRM and rates it as a “Strong Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/6/17
Ticker Symbol ETRM
Last Price a/o 8:25 AM EST $5.32
Average Volume 10.46 milion
Market Cap $11.51 million
Sales $0.79 million
Shares Outstanding 2.9 million
Share Float 2.38 million
Shortable No
Optionable Yes
Inside Ownership
Short Float
Short Interest Ratio
Quarterly Return 2919.00%
YTD Return 98.50%
Year Return 120.56%

Sonic Corporation (Nasdaq: SONC) Posts Tasty Results

Sonic Corporation – Nasdaq: SONC

Oklahoma-based Sonic Corporation released financial results and its shares moved higher as a result. Sonic Corporation trades under the ticker symbol SONC on the Nasdaq. The company operates fast food, drive-in restaurants across the United States. The most recent data available shows that there are 3,557 restaurants of which 345 are company owned and the rest are franchised operations.

The released financial results were a mixed bag but mostly positive. Net revenue did not meet expectations, but net income and same store sales did beat consensus estimates. Same store sales were expected to drop 2.4% but the reported figures showed a drop of only 2%. The street expected adjusted earnings of $0.21 per share; however SONC posted $0.24 per share. Sonic Corp. posted $129.6 million in total revenues but the street was expecting $130.6 million.

Sonic Corporation also repurchased about 4% of its shares – about 2 million shares. Sonci’s press release stated that their share repurchase program will be completed in 2017 and has budgeted $122 million for such a purpose. In 2012, SONC had just over 60 million shares outstanding. Since then the shares outstanding has decreased each year and ended 2016 with 48.7 million shares outstanding.

While sales growth has been relatively uninspiring (2012: $544 million and in 2016: $606 million) SONCS shares have experienced solid performance. In 2012 SONC posted $0.60 EPS and in 2016 EPS was $1.32. Eleven firms follow Sonic Corporation. Three give SONC a rating of “Strong Buy”; seven rate SONC a “Hold”; and one gives SONC a “Sell” rating.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/5/17
Ticker Symbol SONC
Last Price a/o 10:33 AM EST $26.45
Average Volume 1 million
Market Cap $1.26   Billion
Sales 606 million
Shares Outstanding 47.95 million
Share Float 44.65 million
Shortable Yes
Optionable Yes
Inside Ownership 0.10%
Short Float 13.11%
Short Interest Ratio 5.74
Quarterly Return 3.12%
YTD Return -1.17%
Year Return -15.19%